旭通控股(01826.HK)擬出售豐展幕牆及譽豐全部股權
格隆匯 8 月 24日丨旭通控股(01826.HK)宣佈,於2020年8月20日,公司全資附屬FDB & Associates Limited擬以519.6萬港元出售豐展幕牆全部已發行股本。同日,其擬以93萬港元出售譽豐全部已發行股份,
據悉,豐展幕牆有限公司為公司間接全資附屬公司,主要從事提供外牆工程及幕牆工程解決方案的設計、供應及安裝服務。譽豐亞洲有限公司為公司的間接非全資附屬公司,主要從事提供有關鑄鋼的打樁連接器的供應及安裝服務以及供應鑽孔工具
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.